In active UC, upadacitinib induced and maintained remission

Research output: Contribution to journalArticlepeer-review


SOURCE CITATION: Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113-28. 35644166.

Original languageEnglish
Pages (from-to)JC113
JournalAnnals of Internal Medicine
Issue number10
Publication statusPublished - 1 Oct 2022


Dive into the research topics of 'In active UC, upadacitinib induced and maintained remission'. Together they form a unique fingerprint.

Cite this